BridgeBio Pharma

BBIO

Market cap $14.9B

- Earliest timepoint in an open-label extension with this magnitude of risk reduction at 44.7% in ACM (p

- Comprehensive submission includes interim Phase 3 FORTIFY data demonstrating BBP-418's rapid, consistent treatment effect and favorable safety profile, with statistically significant and clinically meaningful improvements in ambulation and pulmonary function - Based on ongoing discussions with the FDA, BridgeBio anticipates approval with a U.S. launch anticipated in late 2026/early 2027 - If approved, BBP-418 has the potential to become the first and only therapy for individuals living with LGMD2I/R9 and may represent the first approved treatment for any form of LGMD PALO ALTO, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced the submission of its New Drug Application (NDA) to the FDA for oral BBP-418 for the treatment of individuals living with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

PALO ALTO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that long-term efficacy and safety data in patients with ATTR-CM from the open-label extension (OLE) trial of ATTRibute-CM, its Phase 3 study of acoramidis, will be shared in a late-breaking oral presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in New Orleans, Louisiana on March 28-30, 2026. Additionally, BridgeBio was selected to share three posters on additional OLE data and real-world survey findings.

PALO ALTO, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on March 18, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 29 new employees in restricted stock units for an aggregate of 70,916 shares of the Company's common stock.

Limb-girdle muscular dystrophy type R9 (LGMDR9, formerly 2I) is a rare genetic disease caused by mutations in the FKRP gene.

BridgeBio Pharma, Inc. (BBIO) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups

William Blair initiated coverage on the commercial-stage biotech, highlighting the company's expanding pipeline of treatments targeting rare genetic conditions.

BridgeBio stock popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.

PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data from the interim analysis of FORTIFY, the Phase 3 clinical trial of BBP-418 in patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9), will be shared in a late-breaking oral presentation at the MDA Clinical and Scientific Conference, taking place in Orlando, Florida on March 8-11, 2026. Additionally, an oral presentation from BridgeBio's academic collaborators at Yale School of Medicine, along with four posters, will highlight advances in the understanding of BBP-418 and LGMD2I/R9.